<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39452206</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-6382</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Antibiotics (Basel, Switzerland)</Title><ISOAbbreviation>Antibiotics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Trends in Antimicrobial Consumption in Tertiary Care Hospitals in Costa Rica from 2017 to 2021: A Comparative Analysis of Defined Daily Doses per 100 Bed Days and per 100 Discharges.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">939</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antibiotics13100939</ELocationID><Abstract><AbstractText><b>Background</b>: Antimicrobial consumption (AMC) data in Latin America are scarce and usually spread out across different sources used to make AMC calculations, making it difficult to both standardize and compare regions through similar time frames. The main objective was to analyze AMC trends in Social Security tertiary care hospitals in Costa Rica in the period spanning January 2017 to December 2021, using both the defined daily dose (DDD)/100 bed days and DDD/100 discharges. <b>Methods</b>: This is a retrospective observational study of antimicrobial consumption. Global consumption trends were calculated and expressed as DDD/100 bed days and DDD/100 discharges. Trends in antimicrobial consumption were analyzed using a simple linear regression model to determine potential differences in antimicrobial usage throughout the study's duration. <b>Results</b>: A statistically significant increase in the consumption expressed in DDD/100 discharges was observed in the following groups: carbapenems, 7.6% (trend: 64.68, <i>p</i> &lt; 0.0001), trimethoprim-sulfamethoxazole: 12.6% (trend: 16.45, <i>p</i> &lt; 0.0001), quinolones 9.4% (trend: 36.80, <i>p</i> = 0.02), vancomycin 2.0% (trend: 16.30, <i>p</i> = 0.03), echinocandins: 6.0% (trend: 15.17, <i>p</i> = 0.01) and azole antifungals: 12.10% (trend: 102.05, <i>p</i> &lt; 0.0001). Additionally, a statistically significant increase of 10.30% in the consumption of azole antifungals expressed in DDD/100 bed days was observed (<i>p</i> = 0.0008). In contrast, a statistically significant decrease in consumption, expressed in DDD/100 discharges, was identified for cephalosporins -6.0% (<i>p</i> &lt; 0.0001) and macrolides -16.5% (<i>p</i> &lt; 0.0001). Macrolides also showed a downward trend in consumption, as expressed in DDD/100 bed days (-14.3%, <i>p</i> &lt; 0.0001). According to World Health Organization (WHO) access, watch and reserve (AWaRe) classification trend analysis, only the reserve group showed a statistically significant upward change of 9.2% (<i>p</i> = 0.016). <b>Conclusions</b>: This five-year analysis demonstrated trends over time in overall antimicrobial consumption measured in DDD/100 bed days and DDD/100 discharge rates that correlate. In general, for all antimicrobials, after the implementation of antimicrobial stewardship programs (ASP), a downward trend is reported; in contrast, during the COVID-19 pandemic the AMC shows a general upward trend. The comparison between DDD/100 bed days and DDD/100 discharges allows for complementary comparisons to be made regarding antimicrobial exposure in a clinical setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernández-Barrantes</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0000-3186-4619</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Hospital San Juan de Dios, Caja Costarricense de Seguro Social, San José 10103, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Esquivel</LastName><ForeName>Allan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6633-771X</Identifier><AffiliationInfo><Affiliation>School of Medicine, University of Costa Rica, San José 11501, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernández-Soto</LastName><ForeName>Luis Esteban</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, University of Costa Rica, San José 11501, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramírez-Cardoce</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5337-1030</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital San Juan de Dios, Caja Costarricense de Seguro Social, San José 10103, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garro-Zamora</LastName><ForeName>Luis David</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hopital México, Caja Costarricense de Seguro Social, San José 10107, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordero</LastName><ForeName>Jose Castro</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-8441-2309</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital México, Caja Costarricense de Seguro Social, San José 10107, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grau</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8428-1836</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Hospital del Mar, Parc de Salut Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antibiotics (Basel)</MedlineTA><NlmUniqueID>101637404</NlmUniqueID><ISSNLinking>2079-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antimicrobial consumption</Keyword><Keyword MajorTopicYN="N">antimicrobial stewardship</Keyword><Keyword MajorTopicYN="N">defined daily dose</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39452206</ArticleId><ArticleId IdType="pmc">PMC11505327</ArticleId><ArticleId IdType="doi">10.3390/antibiotics13100939</ArticleId><ArticleId IdType="pii">antibiotics13100939</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global action Plan on Antimicrobial Resistance.  [(accessed on 19 May 2024)].  Available online:  https://www.who.int/publications-detail-redirect/9789241509763.</Citation></Reference><Reference><Citation>Murray C.J.L., Ikuta K.S., Sharara F., Swetschinski L., Aguilar G.R., Gray A., Han C., Bisignano C., Rao P., Wool E., et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet. 2022;399:629–655. doi: 10.1016/S0140-6736(21)02724-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02724-0</ArticleId><ArticleId IdType="pmc">PMC8841637</ArticleId><ArticleId IdType="pubmed">35065702</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Antimicrobial Resistance.  [(accessed on 24 February 2020)].  Available online:  https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.</Citation></Reference><Reference><Citation>World Health Organization  GLASS|Global Antimicrobial Resistance Surveillance System (GLASS) Report.  [(accessed on 20 February 2024)].  Available online:  https://www.who.int/publications/i/item/9789241515061.</Citation></Reference><Reference><Citation>CDC  Antimicrobial Resistance. Antibiotic Resistance Threats Report 2019.  [(accessed on 21 May 2024)]; Available online:  https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html.</Citation></Reference><Reference><Citation>Hassoun N., Kassem I.I., Hamze M., El Tom J., Papon N., Osman M. Antifungal Use and Resistance in a Lower–Middle-Income Country: The Case of Lebanon. Antibiotics. 2023;12:1413. doi: 10.3390/antibiotics12091413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12091413</ArticleId><ArticleId IdType="pmc">PMC10525119</ArticleId><ArticleId IdType="pubmed">37760710</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan American Association of Infectology  Guide for the Implementation of an Antimicrobial Stewardship Program at a Hospital Level. Asociación Panamericana de Infectología.  [(accessed on 1 March 2020)].  Available online:  https://apiinfectologia.org/wp-content/uploads/2023/11/manual-PROA_2016.pdf.</Citation></Reference><Reference><Citation>Grau S., Bou G., Fondevilla E., Nicolás J., Rodríguez-Maresca M., Martínez-Martínez L. How to measure and monitor antimicrobial consumption and resistance. Enfermedades Infecc. Y Microbiol. Clin. 2013;31:16–24. doi: 10.1016/S0213-005X(13)70128-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0213-005X(13)70128-9</ArticleId><ArticleId IdType="pubmed">24129285</ArticleId></ArticleIdList></Reference><Reference><Citation>Fondevilla E., Grau S., Echeverría-Esnal D., Gudiol F., VINCat Program Group Antibiotic consumption trends among acute care hospitals in Catalonia (2008–2016): Impact of different adjustments on the results. Expert Rev. Anti-Infect. Ther. 2021;19:245–251. doi: 10.1080/14787210.2020.1814142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2020.1814142</ArticleId><ArticleId IdType="pubmed">32825806</ArticleId></ArticleIdList></Reference><Reference><Citation>Norwegian Institute of Public Health—World Health Organization  ATCDDD—ATC/DDD Index.  [(accessed on 19 May 2024)].  Available online:  https://atcddd.fhi.no/atc_ddd_index/</Citation></Reference><Reference><Citation>Gutiérrez-Urbón J.M., Gil-Navarro M.V., Moreno-Ramos F., Núñez-Núñez M., Paño-Pardo J.R., Periáñez-Párraga L. Indicators of the hospital use of antimicrobial agents based on consumption. Farm. Hosp. 2019;43:94–100.</Citation><ArticleIdList><ArticleId IdType="pubmed">31072287</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Statistic and Census-INEC  Total Population of Costa Rica.  [(accessed on 19 May 2024)].  Available online:  https://inec.cr/poblacion-total.</Citation></Reference><Reference><Citation>The National Health System in Costa Rica  Caja Costarricense de Seguro Social.  [(accessed on 20 May 2024)].  Available online:  https://www.binasss.sa.cr/opac-ms/media/digitales/El%20Sistema%20nacional%20de%20salud%20en%20Costa%20Rica.%20Generalidades.pdf.</Citation></Reference><Reference><Citation>Pan American Health Organization  WHO Model List of Essential Medicines 2021.  [(accessed on 20 May 2024)].  Available online:  https://www.paho.org/es/documentos/22a-lista-modelo-oms-medicamentos-esenciales-ingles.</Citation></Reference><Reference><Citation>Official List of Medicines—CCSS.  [(accessed on 20 May 2024)].  Available online:  https://www.ccss.sa.cr/flip/lom/#pag/1.</Citation></Reference><Reference><Citation>National action plan to fight antimicrobial resistance 2018-2025. Ministry of Health-Costa Rica 2018.  [(accessed on 20 May 2024)].  Available online:  https://www.ministeriodesalud.go.cr/index.php/biblioteca-de-archivos-left/documentos-ministerio-de-salud/vigilancia-de-la-salud/normas-protocolos-guias-y-lineamientos/resistencia-a-los-antimicrobianos/1861-plan-de-accion-nacional-de-lucha-contra-la-resistencia-a-los-antimicrobianos-costa-rica-2018-2025/file.</Citation></Reference><Reference><Citation>Marin G.H., Giangreco L., Dorati C., Mordujovich P., Boni S., Mantilla-Ponte H., Arvez M.J.A., Peña M.L., González M.F.A., Castro J.L., et al. Antimicrobial Consumption in Latin American Countries: First Steps of a Long Road Ahead. J. Prim. Care Community Health. 2022;13:21501319221082346. doi: 10.1177/21501319221082346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21501319221082346</ArticleId><ArticleId IdType="pmc">PMC9021473</ArticleId><ArticleId IdType="pubmed">35438037</ArticleId></ArticleIdList></Reference><Reference><Citation>Díaz-Madriz J.P., Cordero-García E., Chaverri-Fernández J.M., Zavaleta-Monestel E., Murillo-Cubero J., Piedra-Navarro H., Hernández-Guillén M., Jiménez-Méndez T. Impact of a pharmacist-driven antimicrobial stewardship program in a private hospital in Costa Rica. Rev. Panam. De Salud Pública. 2020;44:e57. doi: 10.26633/RPSP.2020.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.26633/RPSP.2020.57</ArticleId><ArticleId IdType="pmc">PMC7498282</ArticleId><ArticleId IdType="pubmed">32973905</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Lara L., Garro-Zamora L.D., Lizano-Barrantes C. Protocolo de profilaxis antibiótica preoperatoria para pacientes ortopédicos del Hospital México: Un análisis de cumplimiento. Farm. Hosp. 2021;45:61–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">33709890</ArticleId></ArticleIdList></Reference><Reference><Citation>Restrepo-Arbeláez N., Garcia-Betancur J.C., Pallares C.J., Villegas M.V. Antimicrobial Stewardship Programs in Latin America and the Caribbean: A Story of Perseverance, Challenges, and Goals. Antibiotics. 2023;12:1342. doi: 10.3390/antibiotics12081342.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12081342</ArticleId><ArticleId IdType="pmc">PMC10452019</ArticleId><ArticleId IdType="pubmed">37627762</ArticleId></ArticleIdList></Reference><Reference><Citation>Collado R., Losa J.E., Álvaro E.A., Toro P., Moreno L., Pérez M. Measurement of antimicrobial consumption using DDD per 100 bed-days versus DDD per 100 discharges after the implementation of an antimicrobial stewardship program. Rev. Esp. Quimioter. 2015;28:317–321.</Citation><ArticleIdList><ArticleId IdType="pubmed">26621177</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuster S.P., Ruef C., Ledergerber B., Hintermann A., Deplazes C., Neuber L., Weber R. Quantitative Antibiotic Use in Hospitals: Comparison of Measurements, Literature Review, and Recommendations for a Standard of Reporting. Infection. 2008;36:549–559. doi: 10.1007/s15010-008-7462-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-008-7462-z</ArticleId><ArticleId IdType="pubmed">19011740</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris A.M. Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their Impact. Curr. Treat. Options Infect. Dis. 2014;6:101–112. doi: 10.1007/s40506-014-0015-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40506-014-0015-3</ArticleId><ArticleId IdType="pmc">PMC4431704</ArticleId><ArticleId IdType="pubmed">25999798</ArticleId></ArticleIdList></Reference><Reference><Citation>Filius P.M.G., Liem T.Y., van der Linden P.D., Janknegt R., Natsch S., Vulto A.G., Verbrugh H.A. An additional measure for quantifying antibiotic use in hospitals. J. Antimicrob. Chemother. 2005;55:805–808. doi: 10.1093/jac/dki093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dki093</ArticleId><ArticleId IdType="pubmed">15814603</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsutsui A., Yahara K., Shibayama K. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. J. Infect. Chemother. 2018;24:414–421. doi: 10.1016/j.jiac.2018.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2018.01.003</ArticleId><ArticleId IdType="pubmed">29428566</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X., Kück U. Cephalosporins as key lead generation beta-lactam antibiotics. Appl. Microbiol. Biotechnol. 2022;106:8007–8020. doi: 10.1007/s00253-022-12272-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-022-12272-8</ArticleId><ArticleId IdType="pmc">PMC9712332</ArticleId><ArticleId IdType="pubmed">36401643</ArticleId></ArticleIdList></Reference><Reference><Citation>Grau S., Hernández S., Echeverría-Esnal D., Almendral A., Ferrer R., Limón E., Horcajada J.P., on behalf of the Catalan Infection Control Antimicrobial Stewardship Program (VINCat-PROA) Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 Pandemic. Antibiotics. 2021;10:943. doi: 10.3390/antibiotics10080943.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10080943</ArticleId><ArticleId IdType="pmc">PMC8388964</ArticleId><ArticleId IdType="pubmed">34438993</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2022.  [(accessed on 19 May 2024)].  Available online:  https://www.who.int/publications-detail-redirect/9789240062702.</Citation></Reference><Reference><Citation>Ajulo S., Awosile B. Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries. PLoS ONE. 2024;19:e0297921. doi: 10.1371/journal.pone.0297921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0297921</ArticleId><ArticleId IdType="pmc">PMC10843100</ArticleId><ArticleId IdType="pubmed">38315668</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control  Antimicrobial consumption in the EU/EEA (ESAC-Net)—Annual Epidemiological Report for 2022.  [(accessed on 15 June 2014)].  Available online:  https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-consumption-europe-2022.</Citation></Reference><Reference><Citation>Miranda-Novales M.G., Flores-Moreno K., López-Vidal Y., Rodríguez-Álvarez M., Solórzano-Santos F., Soto-Hernández J.L., Ponce de León-Rosales S. Antimicrobial resistance and antibiotic consumption in Mexican hospitals. Salud Pública de México. 2020;62:42–49. doi: 10.21149/10543.</Citation><ArticleIdList><ArticleId IdType="doi">10.21149/10543</ArticleId><ArticleId IdType="pubmed">31869560</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W., Feng H., Ma Y., Zhao D., Hu X. Long-term trend of antibiotic use at public health care institutions in northwest China, 2012–2020—A case study of Gansu Province. BMC Public Health. 2023;23:27. doi: 10.1186/s12889-022-14944-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-14944-6</ArticleId><ArticleId IdType="pmc">PMC9814306</ArticleId><ArticleId IdType="pubmed">36604660</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Canada  Canadian Antimicrobial Resistance Surveillance System (CARSS) Report 2022.  [(accessed on 15 June 2024)].  Available online:  https://www.canada.ca/en/public-health/services/publications/drugs-health-products/canadian-antimicrobial-resistance-surveillance-system-report-2022.html.</Citation></Reference><Reference><Citation>Lopez M., Martinez A., Celis Bustos Y., Thekkur P., Nair D., Verdonck K., Perez F. Antibiotic consumption in secondary and tertiary hospitals in Colombia: National surveillance from 2018–2020. Rev. Panam. De Salud Pública. 2023;47:e63. doi: 10.26633/RPSP.2023.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.26633/RPSP.2023.63</ArticleId><ArticleId IdType="pmc">PMC10100593</ArticleId><ArticleId IdType="pubmed">37082536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolović D., Drakul D., Vujić-Aleksić V., Joksimović B., Marić S., Nežić L. Antibiotic consumption and antimicrobial resistance in the SARS-CoV-2 pandemic: A single-center experience. Front. Pharmacol. 2023;14:1067973. doi: 10.3389/fphar.2023.1067973.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1067973</ArticleId><ArticleId IdType="pmc">PMC10050571</ArticleId><ArticleId IdType="pubmed">37007038</ArticleId></ArticleIdList></Reference><Reference><Citation>Grau S., Fondevilla E., Echeverría-Esnal D., Alcorta A., Limon E., Gudiol F. Widespread increase of empirical carbapenem use in acute care hospitals in Catalonia, Spain. Enfermedades Infecc. Y Microbiol. Clin. 2019;37:36–40. doi: 10.1016/j.eimc.2018.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eimc.2018.03.003</ArticleId><ArticleId IdType="pubmed">29703463</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzales B.E., Mercado E.H., Pinedo-Bardales M., Hinostroza N., Campos F., Chaparro E., Del Águila O., Castillo M.E., Saenz A., Reyes I., et al. Increase of Macrolide-Resistance in Streptococcus pneumoniae Strains After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Lima, Peru. Front. Cell. Infect. Microbiol. 2022;12:866186. doi: 10.3389/fcimb.2022.866186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.866186</ArticleId><ArticleId IdType="pmc">PMC9125093</ArticleId><ArticleId IdType="pubmed">35615398</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Lopes A., Correia S., Leal C., Resende I., Soares P., Azevedo A., Paiva J.-A. Increase of Antimicrobial Consumption in a Tertiary Care Hospital during the First Phase of the COVID-19 Pandemic. Antibiotics. 2021;10:778. doi: 10.3390/antibiotics10070778.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10070778</ArticleId><ArticleId IdType="pmc">PMC8300755</ArticleId><ArticleId IdType="pubmed">34202340</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson R. Emergence of resistant Candida auris. Lancet Microbe. 2023;4:e396. doi: 10.1016/S2666-5247(23)00143-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00143-X</ArticleId><ArticleId IdType="pubmed">37150182</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabre V., Cosgrove S.E., Secaira C., Torrez JC T., Lessa F.C., Patel T.S., Quiros R. Antimicrobial stewardship in Latin America: Past, present, and future. Antimicrob. Steward. Healthc. Epidemiol. 2022;2:e68. doi: 10.1017/ash.2022.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2022.47</ArticleId><ArticleId IdType="pmc">PMC9726506</ArticleId><ArticleId IdType="pubmed">36483374</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>